What is SLU-PP-332? The ERR Agonist and Exercise Mimetic

[Disclaimer: All content provided on this website, including product information and articles, is intended exclusively for educational and informational purposes.]

SLU-PP-332 is a synthetic compound that works as a potent agonist for estrogen-related receptors (ERRs), with strongest binding to ERRα. Researchers are studying it for its potential to enhance mitochondrial activity and energy metabolism.

Animal studies show the compound produces several metabolic improvements, including weight loss, reduced fat, better glucose processing, and increased physical stamina. These findings have made SLU-PP-332 an important tool for scientists studying metabolic disorders, age-related decline, and heart health.

In this article, we explore the science behind SLU-PP-332, examine its mechanisms, and review the research evidence regarding its metabolic and exercise-mimetic properties.

Understanding ERRs and the Need for Agonists

Estrogen-related receptors (ERRs) are orphan nuclear receptors that control energy metabolism throughout the body. Despite their name, they don’t respond to estrogen but are crucial for metabolic processes.

ERRs come in three forms: ERRα, ERRβ, and ERRγ. Scientists have focused mostly on ERRα and ERRγ. These receptors:

• Manage glucose and fatty acid metabolism
• Control mitochondrial formation
• Regulate cellular energy production
• Can mimic exercise-related metabolic improvements when activated

Scientists are especially interested in ERRs because of their strong connection to metabolic health. Compounds that activate these receptors (agonists) help researchers study conditions where metabolism isn’t working properly.

What is SLU-PP-332?

SLU-PP-332 is a synthetic small molecule that functions as a pan-ERR agonist, meaning it activates all three types of estrogen-related receptors (ERRα, ERRβ, and ERRγ). While it shows activity across the entire ERR family, it binds most strongly to ERRα.

Chemical Properties

• Chemical name: 4-hydroxy-N-[(Z)-naphthalen-2-ylmethylideneamino]benzamide
• Molecular formula: C₁₈H₁₄N₂O₂
• Molecular weight: 290.32 g/mol
• Solubility: Dissolves in DMSO at 5 mg/ml

How SLU-PP-332 Works

When SLU-PP-332 binds to ERRs, particularly ERRα, it triggers a cascade of cellular responses that enhance energy metabolism:

1. Boosts mitochondrial production – Increases the number of cellular “power plants”
2. Enhances oxidative phosphorylation – Improves the efficiency of ATP energy production
3. Promotes fat utilization – Activates enzymes responsible for breaking down fatty acids
4. Activates AMPK signaling – Mimics the cellular response typically seen during exercise

Through these mechanisms, SLU-PP-332 effectively “turns up” the metabolic activity in cells, making it a valuable research compound for laboratories studying energy metabolism, mitochondrial function, and related processes.

Preclinical Efficacy in Metabolic Disorders

Animal model research indicates SLU-PP-332 effectively targets multiple aspects of metabolic disorders. These findings suggest the compound may serve as an important research tool for metabolic studies.

Weight Management Effects

Administration of SLU-PP-332 (50 mg/kg twice daily for 12-28 days) in diet-induced obese mice produced remarkable results:

• 18-24% reduction in body weight
• 30-35% decrease in white adipose tissue mass
• Noticeable reduction in adipocyte (fat cell) size¹

Interestingly, SLU-PP-332 didn’t affect food intake in normal mice, suggesting its weight reduction effects weren’t simply due to appetite suppression.

Glucose Metabolism Improvements

Studies demonstrated SLU-PP-332’s beneficial effects on glucose handling:

• 40% improvement in glucose tolerance in obese mouse models
• 25-30% decrease in fasting insulin levels
• Enhanced insulin sensitivity in metabolic syndrome models¹

Liver Health and Lipid Profile

The compound also showed positive effects on broader metabolic parameters:

• Decreased blood levels of total cholesterol, HDL, and triglycerides
• Significant reduction in hepatic steatosis (fatty liver)
• Reduced liver inflammation in obese mice¹

These preclinical findings collectively suggest that SLU-PP-332 represents a valuable compound for laboratory studies investigating metabolic disorders, particularly in research focusing on obesity, impaired glucose metabolism, and related conditions.

SLU-PP-332 as an Exercise Mimetic

One of the most fascinating aspects of SLU-PP-332 is its ability to function as an “exercise mimetic” – a compound that simulates some of the biological effects of physical exercise at the cellular and molecular level.

Performance Results in Research Models

Studies with mice have shown significant improvements in physical capacity:

• 70% longer running time
• 45% greater running distance
• Increased proportion of fast oxidative skeletal muscle fibers (Type IIa)²

These occurred without actual exercise training, highlighting the compound’s unique properties in laboratory settings.

Mechanisms Behind Exercise-Like Effects

SLU-PP-332 activates several pathways typically engaged during aerobic exercise:

• Increases mitochondrial biogenesis – creating more cellular energy producers
• Activates PGC1 alpha – a master regulator of energy metabolism²
• Stimulates sirtuin 1 protein – involved in cellular stress response³
• Influences mTOR signaling – important for muscle adaptation

These molecular changes mirror some of the adaptations normally seen with endurance training. The exercise-mimetic properties of SLU-PP-332 open up interesting research avenues for laboratories studying exercise biology, metabolic adaptations, and potential applications in conditions where physical activity capacity is limited.

Protective Effects on Age-Related Organ Function

Research indicates that SLU-PP-332’s benefits extend beyond metabolic improvements, with promising effects on aging processes and organ function in laboratory models.

Age-Related Cellular Protection

Studies in aged rodent models have demonstrated that SLU-PP-332 can:

• Restore mitochondrial respiration rates in organs like the kidney and liver
• Reduce age-associated inflammation markers (IL-6 and TNF-α)
• Decrease oxidative damage to mitochondrial DNA
• Improve cellular cleanup processes (autophagy and mitophagy)
• Reduce fibrotic tissue changes in vital organs³

Cardiovascular Benefits

SLU-PP-332 has shown notable cardioprotective effects in preclinical heart failure models:

• Improved ejection fraction against pressure overload-induced heart failure
• Reduced cardiac fibrosis without affecting cardiac hypertrophy
• Activated genes involved in fatty acid metabolism and mitochondrial function
• Normalized metabolic profiles in fatty acid/lipid and TCA cycle pathways
• Induced autophagy in cardiomyocytes (heart muscle cells)⁴

Kidney Protection

Research suggests SLU-PP-332 may support kidney health through:

• Mimicking caloric restriction’s protective effects
• Reducing albuminuria (a marker of kidney damage)
• Preserving podocytes (essential filtration cells)⁵

The compound’s ability to address foundational cellular processes related to energy production and utilization appears to provide wide-ranging benefits across multiple organ systems.

This makes SLU-PP-332 particularly interesting for laboratories studying the connections between metabolism, aging, and organ function.

SLU-PP-332 vs. Other Compounds

SLU-PP-332 works differently than standard metabolic disorder treatments. While existing therapies typically target appetite reduction, insulin pathways, or lipid management, SLU-PP-332 boosts energy use by activating mitochondrial function through ERR stimulation.

This approach mimics the metabolic benefits of exercise at the cellular level without affecting appetite, as shown in the preclinical studies. As a pan-ERR agonist that activates all three ERR subtypes, SLU-PP-332 provides complete coverage of ERR-regulated pathways compared to more limited compounds.

Future Research Directions for SLU-PP-332

Recent lab studies of SLU-PP-332 have revealed several promising research directions. Based on current data, this compound may be valuable for laboratory investigations in:

• Metabolic conditions (type 2 diabetes, obesity)
• Liver function (NASH/NAFLD models)
• Heart research (cardiac failure models)
• Muscle studies (sarcopenia, exercise physiology)
• Mitochondrial function
• Kidney research (aging models)
• Lifespan and health studies

Scientists might conduct thorough safety assessments and long-term studies in various models. Testing SLU-PP-332 alongside other research compounds could reveal potential synergies. Creating improved analogs, especially those that cross the blood-brain barrier more effectively, might extend research into neurological applications.

As research continues, understanding how each ERR subtype (α, β, and γ) contributes to SLU-PP-332’s effects will provide key insights into its mechanisms. Identifying relevant biomarkers could help measure responses to ERR activation in experimental models.

Takeaway

SLU-PP-332 marks a major breakthrough in metabolic research as a strong pan-ERR agonist. It boosts mitochondrial function and energy metabolism, showing great promise in preclinical studies across areas from metabolic disorders to protecting aging tissues.

By triggering cellular pathways that mimic exercise adaptations, this compound may provide researchers a powerful tool to explore new approaches to metabolic health. Though current evidence comes from preclinical models, SLU-PP-332 serves as a key reference compound in ERR-targeted research, with wide implications for understanding basic cellular energy processes and their applications.

Referenced Sources

1. Billon, C., Schoepke, E., Avdagic, A., Chatterjee, A., Butler, A. A., Elgendy, B., Walker, J. K., & Burris, T. P. (2024). A Synthetic ERR Agonist Alleviates Metabolic Syndrome. The Journal of pharmacology and experimental therapeutics, 388(2), 232–240. https://doi.org/10.1124/jpet.123.001733 ↩︎
2. Billon, C., Sitaula, S., Banerjee, S., Welch, R., Elgendy, B., Hegazy, L., Oh, T. G., Kazantzis, M., Chatterjee, A., Chrivia, J., Hayes, M. E., Xu, W., Hamilton, A., Huss, J. M., Zhang, L., Walker, J. K., Downes, M., Evans, R. M., & Burris, T. P. (2023). Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity. ACS chemical biology, 18(4), 756–771. https://doi.org/10.1021/acschembio.2c00720 ↩︎
3. Wang, X. X., Myakala, K., Libby, A. E., Krawczyk, E., Panov, J., Jones, B. A., Bhasin, K., Shults, N., Qi, Y., Krausz, K. W., Zerfas, P. M., Takahashi, S., Daneshpajouhnejad, P., Titievsky, A., Taranenko, E., Billon, C., Chatterjee, A., Elgendy, B., Walker, J. K., Albanese, C., … Levi, M. (2023). Estrogen-Related Receptor Agonism Reverses Mitochondrial Dysfunction and Inflammation in the Aging Kidney. The American journal of pathology, 193(12), 1969–1987. https://doi.org/10.1016/j.ajpath.2023.07.008 ↩︎
4. Xu, W., Billon, C., Li, H., Wilderman, A., Qi, L., Graves, A., Rideb, J., Zhao, Y., Hayes, M., Yu, K., Losby, M., Hampton, C., Adeyemi, C., Hong, S., Nasiotis, E., Fu, C., Oh, T., Fan, W., Downes, M., Welch, R., Evans, R., Milosavljevic, A., Walker, J., Jensen, B., Pei, L., Burris, T., & Zhang, L. (2023). Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function. Circulation, 149, 227 – 250. https://doi.org/10.1161/CIRCULATIONAHA.123.066542 ↩︎
5. Nasri, H. (2024). New hopes on “SLU-PP-332” as an effective agent for weight loss with indirect kidney protection efficacy; a nephrology point of view. Journal of Renal Endocrinology. https://doi.org/10.34172/jre.2024.25143 ↩︎

Author: Limitless Life Nootropics